Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)

NCT05030025 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1-infection

Interventions

COMBINATION_PRODUCT: abacavir, dolutegravir and lamivudine dispersible tablets
COMBINATION_PRODUCT: Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine

Sponsor

Mylan Inc.

Collaborators

[object Object]